1例头孢他啶/阿维巴坦治疗碳青霉烯耐药肺炎克雷伯菌血流感染患者的药学监护

doi:10.19803/j.1672-8629.20210178

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (11): 1258-1261.
DOI: 10.19803/j.1672-8629.20210178

1例头孢他啶/阿维巴坦治疗碳青霉烯耐药肺炎克雷伯菌血流感染患者的药学监护

任昭¹, 刘佳¹, 王玉敏^2,*, 王月¹, 谢清¹

¹航天中心医院药剂科,北京 100049;
²航天中心医院呼吸与危重症医学科,北京 100049

收稿日期:2021-03-05 发布日期:2022-11-17
通讯作者: ^*王玉敏,女,博士,副主任医师,呼吸病学。E-mail：nmgwangym@aliyun.com
作者简介:任昭,女,硕士,主管药师,临床药学。
基金资助:
北京市海淀区卫生健康发展科研委培育计划（HP2021-19-50701）

Pharmaceutical care of a case of carbapenem resistant Klebsiella pneumoniae bloodstream infection treated with ceftazidime/verbatan

REN Zhao¹, LIU Jia¹, WANG Yumin^2,*, WANG Yue¹, XIE Qing¹

¹Department of Pharmacy, Aerospace Center Hospital, Beijing 100049, China;
²Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Beijing 100049, China

Received:2021-03-05 Published:2022-11-17

摘要/Abstract

摘要： 目的探讨临床药师在碳青霉烯耐药肺炎克雷伯菌血流感染药物治疗中的作用。方法临床药师参与1例碳青霉烯耐药肺炎克雷伯菌血流感染患者的治疗过程,结合专业知识,根据患者实际情况,建议采用注射用头孢他啶阿维巴坦单药治疗方案,并对用药的有效性和安全性进行监护。结果医生采纳临床药师建议,经治疗后患者体温正常,炎症指标好转,血培养显示无细菌生长。结论临床药师通过参与临床工作,及时掌握新药的相关知识,为临床医生提供药学信息服务,保障用药的合理性、安全性。

关键词: 肺炎克雷伯菌, 碳青霉烯耐药, 头孢他啶/阿维巴坦, 药学监护

Abstract: Objective To investigate the role of clinical pharmacists in the treatment of bloodstream infection caused by carbapenem resistant Klebsiella pneumoniae. Methods Clinical pharmacists participated in the treatment of a patient with bloodstream infection caused by carbapenem resistant Klebsiella pneumoniae. Based on their expertise and the condition of the patient, the pharmacists recommended ceftazidime/avibactam monotherapy, and monitored the effectiveness and safety of medication. Results The clinicians took the advice of clinical pharmacists so that the patient’s temperature returned to normal, the inflammatory indexes were improved, and the blood culture showed no bacterial growth. Conclusion By participating in clinical practice, clinical pharmacists can quickly learn about the usage of new drugs, provide pharmaceutical services for clinicians, and ensure the rationality and safety of drug use.

Key words: Klebsiella pneumoniae, carbapenem resistant, ceftazidime/avibactam, pharmaceutical care

中图分类号:

R969.3

任昭, 刘佳, 王玉敏, 王月, 谢清. 1例头孢他啶/阿维巴坦治疗碳青霉烯耐药肺炎克雷伯菌血流感染患者的药学监护[J]. 中国药物警戒, 2022, 19(11): 1258-1261.

REN Zhao, LIU Jia, WANG Yumin, WANG Yue, XIE Qing. Pharmaceutical care of a case of carbapenem resistant Klebsiella pneumoniae bloodstream infection treated with ceftazidime/verbatan[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1258-1261.

参考文献

[1] POURNARAS S, PROTONOTARIOU E, VOULGARI E, et al.Clonal spread of KPC -2 carbapenemase -producing Klebsiella pneumoniae strains in Greece[J]. Journal of Antimicrobial Chemotherapy, 2009, 64(2): 348-52.
[2] European Centre for Disease Prevention and Control. Annual epidemiological report on communicable diseases in Europe[M].Stockholm: European Centre for Disease Prevention and Control,2014.
[3] Centers for disease control and prevention. Facility guidance for control of carbapenem- resistant Enterobacteriaceae (CRE) 2015 update[S/OL].[2020-10-18]. https://www.cdc.gov/hai/pdfs/cre/cre-guidance-508.pdf.
[4] CHEN L, MATHEMA B, CHAVDA KD, et a1. Carbapenemase producing Klebsiella pneumoniae:molecular and genetic decoding[J]. Trends Microbiol, 2014, 22(12): 686-696.
[5] YANG L, ZHANG ZJ, QIN XS.Carbapenem-resistanct Klebsiella pneumoniae:Resistant mechanisms and risk factors[J]. Chinese Journal of Antibiotics(中国抗生素杂志), 2018, 43(2): 53-58.
[6] TZOUVELEKIS LS, MARKOGIANNAKIS A, PSICHOGIOU M, et al.Carbapenemases in Klebsiella pneumoniae and other enterobacteriaceae: an evolving crisis of global dimensions[J]. Clinical Microbiology Reviews, 2012, 25(4):682-707.
[7] SHI Y, HUANG Y, ZHANG TT, et al.Chinese guidelines for the diagnosis and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adults (2018 Edition)[J]. Journal of Thoracic Disease, 2019, 11(6): 2581-2616.
[8] PAUL M, CARMELI Y, DURANTE-MANGONI E, et al.Combination therapy for carbapenem-resistant Gram-negative bacteria[J]. Journal of Antimicrob Chemother, 2014, 69:2305-2309.
[9] Chinese Society of Hematology, Chinese Medical Association, Chinese Hematology Association, Chinese Medical Doctor Association.Management of Carbapenem- resistant Enterobacteriaceae(CRE) infection in patients with hematological malignancies: Chinese consensus(2020)[J]. Chinese Journal of Hematology(中华血液学杂志), 2020, 41(11): 881-889.
[10] SHIELDS RK, NGUYEN MH, CHEN L, et al. Ceftazidime-avibactamis superior to other treatment regimens against carbapenem-resistant Klebsiella pneumonia bacteremia[J]. Antimicrobial Agents and Chemotherapy, 2017, 61(8):AAC.00883-17.
[11] MARIO T, MARIA TE, GIUSEPPE DRF, et al.Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicenter study[J]. J Antimicrob Chemother, 2015, 70(7): 2133-2143.
[12] DAIKOS GL, MARKOGIANNAKIS A.Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?[J]. Clin Microbiol Infect, 2011, 17(8): 1135-1141.
[13] Highlights of prescribing information. Center For Drug Evaluation And Research, U.S. Food and Drug Administration[EB/OL].(2019-03)[2021-01-20].https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206494s005,s006lbl.pdf.
[14] SHIRLEY M.Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections[J]. Drugs, 2018, 78(5): 675-692.
[15] MERDJANH, RANGARAJU M, TARRAL A.Safety and pharmacokinetics of single and multiple ascending doses of avibactamalone and in combination with ceftazidimein healthy male volunteers: results of two randomized, placebo-controlled studies[J]. Clinical Drug Investigation, 2015, 35(5): 307-317.
[16] HAWKEY PM, WARREN RE, LIVERMORE DM, et al. Treatment of infections caused by multidrug-resistant gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party?[J]. Journal of Antimicrobial Chemotherapy, 2018, 73(suppl_3): iii2-iii78.
[17] HU X, ZHANG YM, LIU X, et al.Investigation and suggestion on labeling of 75 instructions for intravenous infusion anti-infective drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(3): 168-170.
[18] Microbiology/Virology Review(s). Center For Drug Evaluation And Research, U.S. Food and Drug Administration[EB/OL].(2019-09-25)[2021-01-15].https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000CllinPharmR.pdf.
[19] CAPONE A, GIANNELLA M, FORTINI D, et al.High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality[J]. Clinical Microbiology and Infection, 2013, 19(1): E23-E30.
[20] ZHOU R, CHENG ZZ.Pharmacists’participation in the treatment of a patient with compiicated abdominai infection secondary to invasive fungai infection[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020,17(2):106-110.

1例头孢他啶/阿维巴坦治疗碳青霉烯耐药肺炎克雷伯菌血流感染患者的药学监护

Pharmaceutical care of a case of carbapenem resistant Klebsiella pneumoniae bloodstream infection treated with ceftazidime/verbatan

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	张夏兰, 袁静, 吴斌, 秦媛媛. 甲磺酸阿帕替尼在恶性肿瘤患者的用药特征分析[J]. 中国药物警戒, 2023, 20(8): 927-932.
[2]	王然, 李轶凡, 刘小艳, 冯欣. 1例妊娠期药物暴露风险的药学监护[J]. 中国药物警戒, 2023, 20(8): 933-934.
[3]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[4]	杨岩, 周德喜, 吴欣俐, 薛淑雅, 丁海华, 张泉, 张云玲. 84例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(3): 334-338.
[5]	姚鑫, 葛秋格, 李亚敏, 王一帆, 李媛媛, 刘志强. 2018~2022年某院新型抗肿瘤药物消化系统不良反应分析[J]. 中国药物警戒, 2023, 20(11): 1273-1278.
[6]	郑金凤, 王景红. 1例多药联用致室性心律失常的药学监护[J]. 中国药物警戒, 2023, 20(11): 1279-1281.
[7]	苏甦, 伍诗琪, 张青霞, 闫素英. 1例吲达帕胺致粒细胞缺乏症患者的药学监护[J]. 中国药物警戒, 2023, 20(11): 1282-1285.
[8]	王燕婷, 张媛媛, 陈怡然, 孙捷, 朱宇, 杨荔艳, 吴知桂, 申丽君, 程敏, 李国辉. 1例恶性肿瘤患者抗感染与抗肿瘤治疗的平衡抉择及药学监护[J]. 中国药物警戒, 2023, 20(10): 1168-1172.
[9]	王祺茹, 左丽, 杜琼, 叶玲, 阮聪, 翟青, 徐蕊. 1例奥拉帕利致Ⅳ度骨髓抑制患者的药学监护[J]. 中国药物警戒, 2023, 20(10): 1176-1180.
[10]	孙雪林, 张攀, 胡欣. 1例维得利珠单抗治疗重症溃疡性结肠炎的药学监护[J]. 中国药物警戒, 2022, 19(7): 782-785.
[11]	唐静雅. 临床药师参与1例肠外营养相关性肝损伤治疗的药学监护[J]. 中国药物警戒, 2022, 19(7): 786-788.
[12]	李雁铭, 赵志刚. 基于循证的伊布替尼不良反应及药学监护[J]. 中国药物警戒, 2022, 19(7): 807-811.
[13]	刘蕾, 张会娟, 钱效森, 孙瑞芳. 1例磺胺脱敏方案治疗干燥综合征合并卡氏肺孢子菌肺炎的药学监护[J]. 中国药物警戒, 2022, 19(6): 680-683.
[14]	周鹏, 杨晶晶. 3种清热解毒类中药注射剂的药学监护[J]. 中国药物警戒, 2022, 19(4): 441-445.
[15]	杜婧,李永辉,阎纳新,郭立杰,刘洋. 1例哌拉西林他唑巴坦治疗肺脓肿患者致药物热及横纹肌溶解症药学监护[J]. 中国药物警戒, 2022, 19(4): 450-452.